Two‐Year Clinical Trial of Oral Alendronate Versus Intravenous Pamidronate in Children With Osteogenesis Imperfecta

@article{Dimeglio2006TwoYearCT,
  title={Two‐Year Clinical Trial of Oral Alendronate Versus Intravenous Pamidronate in Children With Osteogenesis Imperfecta},
  author={Linda Dimeglio and Munro Peacock},
  journal={Journal of Bone and Mineral Research},
  year={2006},
  volume={21}
}
A 2‐year prospective, partially randomized open‐label trial comparing oral alendronate with intravenous pamidronate therapy in children with OI showed equivalence in increasing total body BMD, spine BMD, and linear growth, and decreasing bone turnover and fracture incidence. Children with mild OI had greater responses than severe OI in BMD and growth. 
Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta‐Analysis of Six Randomized Placebo‐Controlled Trials
To assess the effectiveness and safety of oral bisphosphonates in increasing bone mineral density (BMD), reducing fractures, and improving clinical function in patients with osteogenesis imperfectaExpand
Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta
Aim: To evaluate the effect of intravenous pamidronate therapy on everyday activities, well‐being, skeletal pain and bone density in children with osteogenesis imperfecta (OI).
Intravenous pamidronate for treatment of osteogenesis imperfecta in Indian children
TLDR
Five children diagnosed with osteogenesis imperfecta are presented with intravenous pamidronate treatment, which resulted in a decrease of fracture rate and increase in spinal bone mineral density. Expand
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
TLDR
Oral ALN for 2 yr in pediatric patients with OI significantly decreased bone turnover and increased spine areal BMD but was not associated with improved fracture outcomes. Expand
THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
  • Xiao-jie Xu, D. Ma, +8 authors Mei Li
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2016
TLDR
Oral ALN and intravenous ZOL are equally effective at increasing BMD and inhibiting bone turnover in adults with OI, and the treatment may reduce fractures in this study. Expand
Clinical use of bisphosphonates in children
Conclusions: Intravenous bisphosphonates are well tolerated, even in infants and small children, and represent a promising therapeutic tool to prevent the development of bone fractures and to improveExpand
Osteogenesis imperfecta: New treatment options
TLDR
A new approach has been developed to replace mutated genes using mesenchymal stem cells and a construct, which inactivates COL1A1, which may have an effect on the fracture rate in children and adult patients. Expand
Treatment of children with osteogenesis imperfecta
Children with moderate to severe forms of osteogenesis imperfecta (OI) require adequate physiotherapy, rehabilitation and orthopedic surgery. Supportive treatment with bisphosphonates can improve theExpand
Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment
TLDR
It is concluded that monthly intravenous ALN as a maintenance treatment following cyclical PAM administration can be an option for OI children. Expand
Cyclic Pamidronate Therapy in Children with Osteogenesis Imperfecta: Results of Treatment and Follow-up After Discontinuation
BACKGROUND Cyclic intravenous pamidronate treatment is widely used for symptomatic therapy of osteogenesis imperfecta (OI). However, data after discontinuation are very limited. AIM The results ofExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta
TLDR
It is indicated that APD is of value in the symptomatic treatment of children with severe OI and a major improvement in well‐being, pain and activities of daily life is reported. Expand
A Comparison of Oral and Intravenous Bisphosphonate Therapy for Children with Osteogenesis Imperfecta
TLDR
Bone mineral density and fracture rates in children with osteogenesis imperfecta improve with intravenous bisphosphonates and change in biomarkers of bone turnover, fracture incidence, and growth rate are analyzed. Expand
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
TLDR
Disodium pamidronate (APD) was given as monthly intravenous infusions to 28 children and adolescents with severe OI or a milder form of the disease, but with spinal compression fractures to find an effective symptomatic treatment. Expand
Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
TLDR
The results support the findings of Glorieux et al that cyclic administration of intravenous pamidronate in children with OI has beneficial effects with respect to BMD z scores and physical disability. Expand
Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
TLDR
The data support that intravenous pamidronate therapy is safe, increases BMD, and reduces fracture rates in very young children with OI and would seem to be the best available treatment for these children. Expand
Bisphosphonate-induced osteopetrosis.
TLDR
A case of drug-induced osteopetrosis in a 12-year-old boy who had received high doses of pamidronate for nearly three years is described. Expand
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
TLDR
In children with severe osteogenesis imperfecta, cyclic administration of intravenous pamidronate improved clinical outcomes, reduced bone resorption, and increased bone density. Expand
Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study
TLDR
Oral treatment with olpadronate at a daily dose of 10 mg/m2 results in a reduction of fracture risk of long bones in children with osteogenesis imperfecta, and the issue of whether bisphosphonates will alter the natural course of osteogenesisperfecta remains unresolved, and further studies are needed. Expand
Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate
TLDR
It is suggested that both pamidronate and mechanical factors influence bone healing in this cohort of children with moderate to severe OI. Expand
Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)
TLDR
Preliminary but long-term obser- vations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Expand
...
1
2
3
4
5
...